TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Therapeutic Gaming for the Treatment of Attention Deficit Hyperactivity Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DEVICE_FEASIBILITY
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 1. Primary diagnosis of ADHD in accordance with DSM-5. 2. On a current regimen of a stimulant type ADHD medication, such as Vyvanse. 3. Sex: males and females. 4. Age: between 10 and 15 years of age. 5. Stated willingness to comply with all study procedures and availability for the duration of the study, including adherence to medication and play regimen. 6. Are capable, as determined by the investigator, to perform the following:~  1. complete the study log.~ 2. are able to comply with the required study visits. 7. Have given written informed assent along with parents/legal guardians to participate in this study in accordance to local regulations before any trial related activities (other than initial screening) are carried out. 8. Are Minecraft players and have access to a full version of PC/Mac (Java) Minecraft, Xbox Minecraft, or pocket Minecraft version (Android, Kindle) that supports play on Realms. 9. Subjects' parents and subjects both currently have Google accounts and electronic devices to access Google accounts online. 10.Must have an NICHQ Vanderbilt Assessment scored by parents and teacher(s) within the last month, or get an assessment scored by parents and teacher(s) within one week of enrollment and before beginning to play the video game if the subject is in the video game arm). 11.At least one parent and the subject must be proficient in spoken and written English.~Exclusion Criteria:~- 1. Current or past history of substance abuse. 2. Patients who for whatever reason are deemed by the investigator inadequate for participation in this trial (e.g., patients with incapacitating mental illness).~3. Have previously completed or withdrawn from this study after having signed the informed consent/assent document. 4. Lack of proficiency in spoken and written English

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 15 Years
- Healthy Volunteers: f

Study Arms:
- Minecraft (Type: EXPERIMENTAL): This group played the video game under development in Minecraft
- Control (Type: PLACEBO_COMPARATOR): This group played another game.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Anti-inflammatory Effects of Simvastatin

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age: 18 to 75 years of age.~2. Obese (BMI ≥30 kg/m2)~3. LDL cholesterol of ≥100 mg/dl~4. Not taking any vitamins or antioxidants~Exclusion Criteria:~1. Currently using anti-hyperlipidemic therapies~2. Triglycerides \>500 mg/dl.~3. Myocardial infarction, angioplasty/stent placement or coronary artery bypass surgery in the past 6 months.~4. Patient on chronic use of non-steroidal anti-inflammatory drugs or steroids~5. Hepatic disease~6. Renal impairment.~7. History of drug or alcohol abuse~8. Participation in any other concurrent clinical trial~9. Use of an investigational agent or therapeutic regimen within 30 days of study.~10. Smoker~11. Pregnancy~12. Premenopausal women who are not on birth control pills and have not had a hysterectomy or tubal ligation~13. Anemia with hemoglobin \<12 g/dl

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Simvastatin (Type: ACTIVE_COMPARATOR): Obese subjects with elevated cholesterol
- Ezetimibe (Type: ACTIVE_COMPARATOR): Obese subjects with elevated cholesterol

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Celiac Disease and Unexplained Iron Deficiency in a Primary Care Setting

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: None
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Active outpatients in the Providence Internal Medicine Residency Clinic, Family Medicine Residency Clinics, or Providence Internal Medicine Clinic~2. Demographic Age \> 18 years. Diagnostic criteria: markers of iron deficiency at last check are defined as MCV\<80 fL, Iron Sat\<20% or ferritin\<30 ng/mL.~3. Patient signs informed consent document and HIPAA authorization for release of personal health information.~4. Ability to understand procedures and comply with them for one year duration of study~Exclusion Criteria:~1. Any documented significant acute or chronic blood loss, per medical record review or self- report (see Appendix B). Significant blood loss includes~   1. Acute blood loss requiring iron treatment or transfusions within 1 year prior to the above measure of iron deficiency~  2. Chronic blood loss (such as menorrhagia, GI bleeding, hemoptysis, hematuria, chronic nose bleeds, hemolysis, regular blood donations, or major trauma requiring transfusion or iron therapy)~  3. Thalassemia or other major hemolytic diseases.~2. Prior diagnosis of celiac disease, or other documented cause of iron malabsorption.~3. Women who are currently pregnant, or who were pregnant with 6 months prior to time of last testing.~4. Those currently or recently on chemotherapy (within the last 6 months)~5. Those with prior gastric resection or bariatric surgery~6. Those with advanced chronic kidney disease (stage 4 or 5)~7. Any other reasons that, in the investigators' opinion, may prevent compliance with protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Intrathecal Rituximab in Lymphoid Malignancies Involving Central Nervous System

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients must have relapsed or refractory CD20+ lymphoid malignancies with either documented CNS involvement or peripheral nerve infiltration.~2. Patients 3 years of age and older are eligible after 3 patients (age 15 or older) have been treated and did not experience a dose limiting toxicity. Patient 3 to 15 years of age will follow the dose escalation schema independent of the adults.~3. ECOG performance status measure will be used. (ECOG Performance Status less than or equal to 3)~4. Adequate liver function (bilirubin less than or equal to 3 mg/dL within 24 hours of enrollment)~5. Adequate renal function (serum creatinine less than or equal to 3 mg/dL within 24 hours of enrollment)~6. Urine pregnancy test for women of childbearing potential (defined as not post-menopausal for 12 consecutive months or no previous surgical sterilizations). A negative urine pregnancy test is required within 48 hours of initiating study drug.~7. Signed informed consent~Exclusion Criteria:~1. Known active meningeal infection~2. History of severe infusion reaction to any monoclonal antibody

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intrathecal Rituximab (Type: EXPERIMENTAL): Phase I Starting Dose: Rituximab administered via lumbar puncture at dose of 10 - 25 mg twice weekly according to the dose escalation.~Phase II Rituximab Starting Dose: Maximum tolerated dose from Phase I.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Doubleblinded RCT of the Omnilux on Lower Extremity Surgical Wounds Left to Heal by Second Intention

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Surgical defect on the lower extremity left to heal by secondary intention.~* If women of child bearing potential, contraceptive measures should be used~* Maximum size of wound is 5cm x5cm; there is no minimum size for the wound.~Exclusion Criteria:~* History of porphyria photosensitive eruptions, diabetes mellitus, history of venous insufficiency, known history of peripheral arterial disease (ABI \<0.8)~* Use of any ointments or creams containing photosensitizers (coumarins or porphyrins) should be discontinued for 2 weeks prior~* Use of systemic or local retinoids for the past 6 months.~* Current pregnancy or breastfeeding~* History of metastatic cancer.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Sham Group (Group 1) (Type: SHAM_COMPARATOR): This group will receive 4 sessions of Omnilux sham light, starting 1 week after the surgery. Frequency: 1 session every week (+/- 3 days), for 4 weeks. Session duration: 20 minutes
- Treatment group (Group 2) (Type: EXPERIMENTAL): This group will receive 4 treatment sessions with Omnilux 633nm LED, starting 1 week after the surgery. Frequency: 1 session every week (+/- 3 days), for 4 weeks. Session duration: 20 minutes

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Multicentre, Randomized as a Double Blind Study, Triple Placebo, Comparative of the Efficacy and Safety of an Association Secnidazol-Ciprofloxacin Compared With Amoxicillin-Clavulanic Acid for the Treatment of Uncomplicated Episode of Diverticular Sigmoïditis Among Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult~* Recovering of written and dated informed consent form~* Social Security medical cover~* Left Iliac Fossa (LIF) pain~* Moderate fever (\>37.8°C)~* Sensitivity/defence during LIF palpation~Biological results :~* CRP \> 10mg/L~* NFS \> 10G/L~* Neutrophil Granulocytosis \> 75%~* Radiological results - presence to the scan :diverticul \& pericolic infiltration~Exclusion Criteria:~* Patients treated by antibiotherapy in the last 15 days prior inclusion~* Patients treated by morphinic drug~* Patients treated by anticoagulant drug~* Pregnant or breast-feeding women~* Patients presenting allergy to active principal, to galactose~* Patients having taking part in another study in the last 3 months prior inclusion~* Patients unable to comply with the study requirements~* Patients presenting Chronic affection inconsistent with the study~* Patients presenting high fever~* Patients presenting abdominal contracture~* Patients presenting immunosuppression~* Radiological sign of complication (abscess\>3cm)~* Patients presenting Pathology inconsistent with efficacy evaluatio

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Secnidazol-Ciprofloxacin (Type: EXPERIMENTAL): 2g(single dose) of Secnidazol associated with 1g(2 doses of 500mg)of Ciprofloxacin during 3 days
- Amoxicillin-Clavulanic Acid (Type: ACTIVE_COMPARATOR): 3g (3 doses of 1g) of Amoxicillin-Clavulanic acid during 10 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Five Treatments in Patients With Plantar Warts

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female patient aged 18 years or more.~* Clinical evaluation~* Number of warts lower than 10 on the 2 feet and total diameter of warts lower than 10 cm, whether previously treated or not~* In treated patients, all potentially active treatment on warts since at least one month should be stopped.~* Effective contraception for women of childbearing age~* Immunocompetent patients~* Patient with one or more warts on soles and board feet.~  * MYRMECIE : rounded warts, deep, covered with a stratum corneum more or less thick; after stripping, appear black points, very specific; often painful to pressure. They are lonely, single or not. They could regroup galley thick. The stripping can them to individualize.~ * Mosaic : plate small warts, superficial, often sitting on the heel or Forefoot. Little painful, they are often ignored by the patients when they appear~* Patient affiliated to the French social security.~Exclusion Criteria:~* Patient suspected to be immunocompromised~* Patient aged under 18 years~* Patient refusing to sign the consent~* Pregnant or lactating women~* Plantar calluses~* Known hypersensitivity to imiquimod (Aldara®) or any excipients of the cream (isostearic acid, benzyl alcohol, cetyl alcohol, stearyl alcohol, paraffin, polysorbate 60, sorbitan stearate, glycerol, methyl hydroxybenzoate, propyl hydroxybenzoate, xanthan gum, purified water)~* Known hypersensitivity to 5 fluoro-uracil (Efudix®) or any excipients of gel (stearyl alcohol, Vaseline, polysorbate 60, propyleneglycol, purified water - conservatives: METHYL PARAHYDROXYBENZOATE, PROPYL PARAHYDROXYBENZOATE)~* Contra-indication to Pomade M.O Cochon® (Known allergy to any components)~* Known hypersensitivity to Blenderm®~* Extra plantar concomitant warts (to exclude risk of endogenous recontamination by an extra plantar site)~* Plantar hyperhidrosis making impossible adhesion of plaster.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Salicylate ointment (Type: EXPERIMENTAL): Salicylate ointment under occlusion (pomade M.O Cochon®)
- Imiquimod (Type: EXPERIMENTAL): Imiquimod : Aldara®
- 5-fluoro-uracil (Type: EXPERIMENTAL): 5-fluoro-uracil cream : Efudix®
- Cryotherapy (Type: EXPERIMENTAL): liquid nitrogen : Cryotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Impact of a Strategy Combining Morphine Savings and Anesthesia Technique on the Quality of Post-operative Rehabilitation

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Pregnant woman,~* operated on a scheduled cesarean under spinal anesthesia or urgent under epidural anesthesia, with use of perimedullary morphine~Exclusion Criteria:~* Contraindication to the use of morphine~* Contraindication to local anesthetics~* Urgent cesarean section for maternal pathology: preeclampsia (PE), eclampsia, HELLP syndrome~* Post-operative maternal transfer~* Preoperative opiate treatment~* Patient unable to understand and / or answer a questionnaire in French

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: A Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients With Diffuse Cutaneous Systemic Sclerosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Written informed consent.~2. Male or female between the ages of 18 and 75 years, inclusive, at Screening.~3. Meets the 2013 American College of Rheumatology/European League Against Rheumatism classification criteria for SSc with a total score of ≥9 (Van den Hoogen et al., 2013).~4. Classified as having skin involvement proximal to the elbow and knee (diffuse cutaneous SSc subset by LeRoy and Medsger, 2001).~5. At the time of enrollment, less than or equal to 72 months (6 years) since the onset of the first SSc manifestation, other than Raynaud's phenomenon.~6. Skin thickening from SSc in the forearm suitable for repeat biopsy.~7. mRSS units ≥15 at Screening.~8. FVC ≥45% predicted at Screening, as determined by spirometry.~9. Willing and able to comply with the prescribed treatment protocol and evaluations for the duration of the trial.~Exclusion Criteria:~1. Positive for anti-centromere antibodies with the exception that subjects who are positive for both anti-centromere and anti-topoi

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- HZN-825 300 mg once daily (QD) (Type: EXPERIMENTAL): One set of 2 HZN-825 150mg tablets in the morning and one set of 2 placebo tablets in the evening.
- HZN-825 300 mg twice daily (BID) (Type: EXPERIMENTAL): One set of 2 HZN-825 150mg tablets in the morning and one set of 2 HZN-825 150mg tablets in the evening.
- Placebo (Type: PLACEBO_COMPARATOR): One set of 2 placebo tablets in the morning and one set of 2 placebo tablets in the evening.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Comparison Study of Two Different Surgical Clips During Laparoscopic Urologic Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DEVICE_FEASIBILITY
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All patients ≥ 18 years old with genitourinary malignancy either prostate cancer or kidney renal masses undergoing minimally invasive genitourinary organ removal will be included in this small pilot study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Teleflex HemoLock clip (Type: PLACEBO_COMPARATOR): Patients randomized to the Aesculap U-clip device or the HemoLock clip will undergo their respective surgery (robotic prostatectomy and laparoscopic and robotic renal surgery) as per standard protocols. During the surgical procedure, when primary vascular control is warranted the appropriate clip to which the patient has been randomized will be utilized. Immediate assessment of the vascular pedicle will subsequently occur
- Aesculap U-Clip (Type: ACTIVE_COMPARATOR): Patients randomized to the Aesculap U-clip device or the HemoLock clip will undergo their respective surgery (robotic prostatectomy and laparoscopic and robotic renal surgery) as per standard protocols. During the surgical procedure, when primary vascular control is warranted the appropriate clip to which the patient has been randomized will be utilized. Immediate assessment of the vascular pedicle will subsequently occur.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Lovastatin in Reducing Side Effects After Radiation Therapy in Women With Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of invasive or in situ epithelial cancer of the breast~  * Stage 0, I, or II (Tis, T1, or T2) disease~ * Unifocal disease (single focus that can be encompassed by breast-conserving surgery)~* Has undergone prior surgical resection of the primary lesion (lumpectomy) and axillary nodal evaluation (if invasive disease is present)~  * Negative surgical margins (≥ 1 mm)~* Planning to undergo radiotherapy with either standard external beam radiotherapy or accelerated partial breast irradiation (interstitial or balloon brachytherapy)~* No Paget disease of the nipple~* No evidence of distant metastases~* Hormone receptor status not specified~PATIENT CHARACTERISTICS:~* Menopausal status not specified~* Karnofsky performance status 70-100%~* Transaminases \< 3 times upper limit of normal (ULN)~* Creatine kinase \< 5 times ULN~* Creatinine clearance ≥ 30 mL/min~* Negative pregnancy test~* No active liver or muscle disease~* No history of collagen vascular disease (e.g., systemic lupus erythematosus, scleroderma, or dermatomyositis)~* History of prior malignancy allowed provided life expectancy is ≥ 4 years~* No major medical or psychiatric illness that, in the investigator's opinion, would prevent completion of study treatment or interfere with follow-up~* No contraindication to an HMG-coA-reductase inhibitor~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* No prior radiotherapy to the breast, lung, or mediastinum~  * Prior radiotherapy to the contralateral breast allowed~* No chemotherapy for ≥ 2 weeks prior to, during, and for ≥ 2 weeks after completion of radiotherapy~* No concurrent cytochrome P450 3A4 inhibitors~* Concurrent HMG-coA-reductase inhibitor allowed provided patient is able to switch to 20 mg of lovastatin per day~* Concurrent tamoxifen or an aromatase inhibitor allowed

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Supportive care (lovastatin) (Type: EXPERIMENTAL): Patients undergo 25-28 fractions of standard whole-breast irradiation followed by a boost to the tumor bed or 10 fractions of accelerated partial-breast irradiation with balloon brachytherapy BID over 5-10 days. Patients also receive lovastatin PO QD for 12 months beginning on day 1 of radiation therapy. Treatment continues in the absence of disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues